Literature DB >> 19869948

SPECIFIC CUTANEOUS REACTIONS AND CIRCULATING ANTIBODIES IN THE COURSE OF LOBAR PNEUMONIA : II. CASES TREATED WITH ANTIPNEUMOCOCCIC SERA.

M Finland1, W D Sutliff.   

Abstract

1. Characteristic cutaneous responses to the type-specific protein-free carbohydrates of both Type I and Type II pneumococci have been "produced" in cases of lobar pneumonia due to either of these types by the intravenous injection of concentrated bivalent (Types I and II) antipneumococcic sera (Felton). 2. A positive cutaneous response to the specific polysaccharide of Type II pneumococci has been passively transferred from human cases convalescing from this infection to a patient suffering from pneumonia due to this organism. 3. The cutaneous responses to the type-specific polysaccharides and circulating antibodies were studied in 51 cases of lobar pneumonia. Positive cutaneous reactions were, in most instances, associated with recovery, even when purulent complications were present. Failure to elicit a positive reaction was usually followed by a fatal outcome. 4. The positive reactions in patients who were treated with concentrated sera and recovered were most often elicited within 24 hours after the first dose and after a total of 40 cc. had been given. 5. The positive skin reactions obtained after the administration of specific antisera were associated with the presence of mouse protective antibodies and agglutinins in the sera of the patients. 6. The immune reactions in serum treated cases receiving repeated inoculations with the specific carbohydrates disappeared more rapidly than in similar cases receiving no antiserum. It is suggested that the administration of antisera in someway interferes with the production of antibodies by the intracutaneously injected carbohydrates.

Entities:  

Year:  1931        PMID: 19869948      PMCID: PMC2132058          DOI: 10.1084/jem.54.5.653

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  8 in total

1.  CERTAIN ASPECTS OF MOUSE PROTECTION TESTS FOR ANTIBODY IN PNEUMOCOCCUS PNEUMONIA.

Authors:  F T Lord; E L Persons
Journal:  J Exp Med       Date:  1931-01-31       Impact factor: 14.307

2.  IMMUNOLOGICAL RELATIONSHIPS OF CELL CONSTITUENTS OF PNEUMOCOCCUS : SECOND PAPER.

Authors:  O T Avery; M Heidelberger
Journal:  J Exp Med       Date:  1925-08-31       Impact factor: 14.307

3.  PRODUCTION OF HETEROGENETIC ANTIBODIES WITH MIXTURES OF THE BINDING PART OF THE ANTIGEN AND PROTEIN.

Authors:  K Landsteiner; S Simms
Journal:  J Exp Med       Date:  1923-07-31       Impact factor: 14.307

4.  CUTANEOUS REACTIONS IN PNEUMONIA. THE DEVELOPMENT OF ANTIBODIES FOLLOWING THE INTRADERMAL INJECTION OF TYPE-SPECIFIC POLYSACCHARIDE.

Authors:  T Francis; W S Tillett
Journal:  J Exp Med       Date:  1930-09-30       Impact factor: 14.307

5.  IMMUNOLOGICAL REACTIONS OF THE ISOLATED CARBOHYDRATE AND PROTEIN OF PNEUMOCOCCUS.

Authors:  O T Avery; H J Morgan
Journal:  J Exp Med       Date:  1925-08-31       Impact factor: 14.307

6.  SPECIFIC CUTANEOUS REACTIONS AND CIRCULATING ANTIBODIES IN THE COURSE OF LOBAR PNEUMONIA : I. CASES RECEIVING NO SERUM THERAPY.

Authors:  M Finland; W D Sutliff
Journal:  J Exp Med       Date:  1931-10-31       Impact factor: 14.307

7.  CUTANEOUS REACTIONS TO THE POLYSACCHARIDES AND PROTEINS OF PNEUMOCOCCUS IN LOBAR PNEUMONIA.

Authors:  W S Tillett; T Francis
Journal:  J Exp Med       Date:  1929-10-31       Impact factor: 14.307

8.  ANAPHYLAXIS WITH THE TYPE-SPECIFIC CARBOHYDRATES OF PNEUMOCOCCUS.

Authors:  O T Avery; W S Tillett
Journal:  J Exp Med       Date:  1929-01-31       Impact factor: 14.307

  8 in total
  2 in total

1.  Novel PCR-restriction fragment length polymorphism method for determining serotypes or serogroups of Streptococcus pneumoniae isolates.

Authors:  Sarah L Batt; Bambos M Charalambous; Timothy D McHugh; Siobhan Martin; Stephen H Gillespie
Journal:  J Clin Microbiol       Date:  2005-06       Impact factor: 5.948

2.  THE VALUE OF THE SKIN TEST WITH TYPE-SPECIFIC CAPSULAR POLYSACCHARIDE IN THE SERUM TREATMENT OF TYPE I PNEUMOCOCCUS PNEUMONIA.

Authors:  T Francis
Journal:  J Exp Med       Date:  1933-03-31       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.